Lantheus Medical Imaging is highlighting clinical data that show reductions in radiation exposure and improved image quality with flurpiridaz F-18 PET myocardial perfusion imaging (MPI) compared to SPECT MPI.
The data were collected in the first of Lantheus' phase III clinical trials for the radiopharmaceutical. It will be presented at the American Society of Nuclear Cardiology (ASNC) annual meeting in Boston by Dr. Jamshid Maddahi of the University of California, Los Angeles (UCLA).
The data build upon the company's phase II findings and offer further information regarding the benefit-risk assessment of the agent in myocardial perfusion imaging, according to the firm.
